Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:CDAK Codiak BioSciences (CDAK) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis Get Codiak BioSciences alerts: Email Address About Codiak BioSciences Stock (NASDAQ:CDAK) 30 days 90 days 365 days Advanced Chart Ad Investors AlleyForget Trump and KamalaForget Trump and Kamala. I don't care who you vote for - This calendar is the only thing that matters right now.Download my Dividend Calendar here Get Codiak BioSciences alerts:Sign Up Key Stats Today's Range$0.0016▼$0.001650-Day Range N/A52-Week Range$0.05▼$6.98VolumeN/AAverage Volume1.37 million shsMarket Capitalization$58,928.00P/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewCodiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12 exosome therapeutic candidates for the treatment of various solid tumors. The company is also developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor; and exoVACC, a modular platform for constructing precision vaccines. It has a collaboration agreement with the Jazz Pharmaceuticals Ireland Limited, Sarepta Therapeutics, Inc., Kayla Therapeutics S.A.S., Washington University, Ragon Institute of MGH, MIT, and Harvard. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Read More… Forget Trump and Kamala (Ad)Forget Trump and Kamala. I don't care who you vote for - This calendar is the only thing that matters right now.Download my Dividend Calendar here Receive CDAK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Codiak BioSciences and its competitors with MarketBeat's FREE daily newsletter. Email Address CDAK Stock News HeadlinesMarvel Biosciences Corp MRVLJanuary 13, 2024 | morningstar.comMariana Oncology Expands Management Team, Appoints Linda Bain Chief Operating Officer and Chief Financial OfficerMay 19, 2023 | finance.yahoo.comHow the US Will Win the Great Lithium RaceChina spent $60B+ on lithium infrastructure in the past decade. It possesses 7.9% of the world’s supply, but it processes 70-80%. Now the US is coming over the top by investing $700B+ into domestic supply with the IRA and Bi-partisan Infrastructure Bill.September 20, 2024 | DealMaker (Ad)CDAK.OApril 15, 2023 | reuters.comHow Does Codiak BioSciences Inc (CDAK) Stock Rank on Wall Street Friday?April 2, 2023 | benzinga.comCodiak BioSciences Files For Chapter 11 BankruptcyMarch 27, 2023 | finance.yahoo.comCodiak BioSciences Shares Hit 52-Week Low After Bankruptcy FilingMarch 27, 2023 | marketwatch.comStruggling MD Anderson spinout files for bankruptcy protectionMarch 27, 2023 | bizjournals.comSee More Headlines CDAK Stock Analysis - Frequently Asked Questions How were Codiak BioSciences' earnings last quarter? Codiak BioSciences, Inc. (NASDAQ:CDAK) announced its quarterly earnings results on Thursday, November, 4th. The company reported ($0.97) earnings per share for the quarter, missing analysts' consensus estimates of ($0.85) by $0.12. The company earned $1.16 million during the quarter, compared to analysts' expectations of $2.87 million. Codiak BioSciences had a negative net margin of 51.13% and a negative trailing twelve-month return on equity of 109.51%. When did Codiak BioSciences IPO? Codiak BioSciences (CDAK) raised $82 million in an initial public offering on Wednesday, October 14th 2020. The company issued 5,500,000 shares at $14.00-$16.00 per share. Goldman Sachs, Evercore ISI, William Blair and Wedbush PacGrow served as the underwriters for the IPO. Company Calendar Last Earnings11/04/2021Today9/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:CDAK CUSIPN/A CIK1659352 Webwww.codiakbio.com Phone617-949-4100FaxN/AEmployees102Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.69) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-37,160,000.00 Net Margins-51.13% Pretax Margin-51.13% Return on Equity-109.51% Return on Assets-34.44% Debt Debt-to-Equity Ratio0.66 Current Ratio4.24 Quick Ratio4.24 Sales & Book Value Annual Sales$33.57 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$2.39 per share Price / Book0.00Miscellaneous Outstanding Shares36,830,000Free Float33,810,000Market Cap$58,928.00 OptionableNot Optionable Beta3.71 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report This page (NASDAQ:CDAK) was last updated on 9/20/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredHow the US Will Win the Great Lithium RaceChina spent $60B+ on lithium infrastructure in the past decade. It possesses 7.9% of the world’s supply, but i...DealMaker | SponsoredThe election trade you can't losePolitics is an unpredictable game. But no matter what happens in the next few months... There's one thin...Investors Alley | SponsoredAre You Ready for a Small-Cap Rally?Jeff Bezos has just made a bold move into Quantum Computing as a Service (QaaS), a technology set to disrupt i...InvestorPlace | SponsoredMust-Know for Trading OptionsOptions are becoming increasingly popular among investors – with demand hitting record highs for 3 years in a ...Unstoppable Prosperity | SponsoredUnlock the Secret to Easy Wins with Iron CondorsDiscover the power of Iron Condor trades – a low-risk, high-reward strategy that allows you to profit consiste...Netpicks | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Codiak BioSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Codiak BioSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.